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The complex relation between thrombotic thrombocytopenic purpura (TTP) and pregnancy is 
concisely reviewed. Pregnancy is a very strong trigger for acute disease manifestation in patients 
with hereditary TTP caused by double heterozygous or homozygous mutations of ADAMTS13 (A 
Disintegrin And Metalloprotease with ThromboSpondin type 1 domains, nr. 13). In several affected 
women disease onset during their first pregnancy leads to the diagnosis of hereditary TTP. Without 
plasma treatment mother and especially fetus are at high risk of dying. The relapse risk during a next 
pregnancy is almost 100% but regular plasma transfusion starting in early pregnancy will prevent 
acute TTP flare-up and may result in successful pregnancy outcome. Pregnancy may also constitute a 
mild risk factor for the onset of acute acquired TTP caused by autoantibody-mediated severe 
ADAMTS13 deficiency. Women having survived acute acquired TTP may not be at very high risk of 
TTP relapse during an ensuing next pregnancy but seem to have an elevated risk of preeclampsia. 
Monitoring of ADAMTS13 activity and inhibitor titre during pregnancy may help to guide 
management and to avoid disease recurrence. Finally, TTP needs to be distinguished from the much 
more frequent hypertensive pregnancy complications preeclampsia and especially HELLP (Hemolysis, 





















Thrombotic thrombocytopenic purpura (TTP) is a severe, often fatal disease that needs urgent 
diagnosis and initiation of effective treatment (1-3). Conceivably, TTP occurring in a pregnant woman 
may complicate the course of pregnancy posing mother and child at vital risk. Moreover, the 
possibility that pregnancy is a risk situation favouring the onset of acute TTP should be considered. In 
addition, the classic pregnancy complications preeclampsia/eclampsia and especially “Hemolysis, 
Elevated Liver enzymes, Low Platelet count” (HELLP) syndrome have clinical signs and laboratory 
features that partially resemble those in TTP (4), making the differential diagnosis of HELLP syndrome 
versus TTP in pregnancy difficult. 
Here, we present a brief overview on the thrombotic microangiopathies (TMAs), including TTP, 
hemolytic uremic syndrome (HUS) and HELLP syndrome. Then, we focus on the role of pregnancy as 
a trigger of acute disease manifestations in women with congenital severe ADAMTS13 (A Disintegrin 
And Metalloprotease whith ThromboSpondin type 1 domains, nr.13) deficiency, on the outcome for 
mother and fetus and on possible prophylactic and therapeutic interventions. Finally, we examine 
whether pregnancy also constitutes a risk for the onset of acute acquired TTP caused by 
autoantibody-mediated severe ADAMTS13 deficiency and/or whether women having survived an 
acute acquired TTP are prone to suffer from disease recurrence during a subsequent pregnancy and 
whether there is any fetal or maternal risk besides an acute TTP flare-up. 
 
Brief Overview of Thrombotic Microangiopathies (TMAs) 
Thrombotic thrombocytopenic purpura (TTP) was first described by Moschcowitz in 1924 (5) and the 
diagnostic pentad of clinical findings, i.e. microangiopathic hemolysis with red cell fragmentation, 
thrombocytopenia, neurologic signs or symptoms, renal dysfunction and fever, was reported by 
Amorosi and Ultmann in 1966 (6) after reviewing some 250 published patients and adding 16 own 
cases. Patients nowadays clinically diagnosed with acute TTP have in most instances a severe 
functional deficiency of the von Willebrand factor (VWF)-cleaving protease, ADAMTS13 (1,7-10), in 
rare cases caused by homozygous or compound heterozygous mutations of the ADAMTS13 gene 
leading to hereditary TTP (Upshaw-Schulman syndrome, USS) (11,12) and more often mediated by 
inactivating anti-ADAMTS13 autoantibodies leading to acquired TTP (1,3,7-10). The resulting 
extremely adhesive unusually large VWF multimers (13) are responsible for the platelet clumping in 
the microvasculature and the resulting ischemic damage in various organs, including brain, kidney, 
heart and other organs (1-3). 
A disease similar to TTP has been reported as the hemolytic uremic syndrome (HUS) in 1955 (14) and 
is conceptually distinguished from TTP by more pronounced renal failure (2,3). Typical HUS is caused 
by shigatoxin-producing enteropathogenic Escherichia coli or shigella and occurs mainly  in children 
whereas atypical HUS has in recent years been found to be often associated with an 
hyperactivatability of the alternative complement pathway, caused by hypofunctional mutations of 
the complement regulatory proteins CFH, CFI, MCP (CD46), THBD or hyperfunctional mutations of 
CFB or C3 (3,15,16). In about 50% of patients diagnosed with atypical HUS heterozygous mutations in 
one of the above mentioned genes, enhancing alternative complement pathway activation, are 
found and in a small minority of atypical HUS patients autoantibodies inactivating CFH are present 
(3,15,16). The clinical distinction between atypical HUS and TTP is difficult and often not possible at 
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presentation (3) but may be important for optimal therapeutic intervention. Whereas plasma 
exchange (PEX) with replacement of fresh frozen plasma (FFP) and immunosuppression with 
corticosteroids remain the mainstay of treatment in acquired TTP (1-3,16), atypical HUS patients may 
benefit more from complement inhibitory treatment using eculizumab, a monoclonal antibody 
binding to and inhibiting the activation of C5 (3,16,17), even though PEX may be (partially) effective 
as well. 
The distinction of hereditary from acquired TTP may be equally important because acute disease 
bouts in hereditary TTP may be treated with simple FFP infusion (1,18) as opposed to acquired TTP 
where often daily PEX therapy over many days or weeks may be needed to achieve a remission (2,7-
10). Recurrent disease flare-ups in USS can be prevented by regular FFP infusions every 2-3 weeks 
(18), whereas recurrent attacks of acquired ADAMTS13 deficient TTP will have to be treated by PEX 
and their incidence may be reduced by intensified immunosuppression, including rituximab, or by 
splenectomy (1,2,16,19). 
Besides classic hereditary and acquired TTP as well as typical and atypical HUS several other 
conditions may be associated with a similar clinical picture of schistocytic hemolytic anemia, 
thrombocytopenia +/- organ dysfunctions. These heterogeneous conditions have been variably 
referred to as TTP, HUS, TTP-HUS, TTP-like disease or secondary TTP (1) and include mainly 
hematopoietic stem cell transplantation-, disseminated neoplasia-, anticancer agent-, other drug-, 
human immunodeficiency virus-, systemic lupus erythematosus-, severe arterial hypertension- and 
pregnancy-associated thrombotic microangiopathies (TMAs) (2,3,16). 
The pregnancy-associated HELLP syndrome is a severe form of preeclampsia (4) and may mimic acute 
ADAMTS13 deficient TTP. Preeclampsia and HELLP are much more common than acute TTP. Patients 
with HELLP syndrome have normal or moderately decreased ADAMTS13 activity but show increased 
VWF levels, a high VWF propeptide/VWF antigen ratio (suggestive of endothelial 
stimulation/damage) and an increased binding affinity of the VWF A1 domain to platelet glycoprotein 
Ib resembling the situation with the unusually large VWF multimers in severely ADAMTS13 deficient 
TTP (20). In (severe) preeclampsia the antiangiogenic factors, fms-like tyrosine kinase 1 (sFlt-1), an 
antagonist of vascular endothelial growth factor (VEGF) and endoglin, an inhibitor of transforming 
growth factor β (TGF-β) are released from the hypoperfused, hypoxic placenta and elevated in 
plasma (4). In a recent longitudinal study on pregnant women with systemic lupus erythematosus 
and/or antiphospholipid syndrome, several women developing preeclampsia/HELLP syndrome 
showed dysfunctional mutations of MCP, CFI or CFH, presumably leading to enhanced complement 
activation, similar to the constellation in atypical HUS (21). In addition, separate cohorts of 59 (21) or 
11 (22) women suffering from severe preeclampsia/HELLP syndrome without underlying 
autoimmune disease similarly showed an increased prevalence of hypofunctional mutations in MCP, 
CFI or CFH suggesting that impaired complement regulation may be a relevant pathogenetic factor in 
severe preeclampsia/HELLP syndrome (21,22) as well as in atypical HUS (3,15,16). 
 
Pregnancy and hereditary TTP 
Among the 23 patients of 19 unrelated families with severe constitutional VWF-cleaving protease 
deficiency published in 2001, 4 of 10 females belonging to two different families had a first acute TTP 
bout during their first pregnancies whereas their two brothers having the same severe VWF-cleaving 
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protease deficiency were still asymptomatic at ages of 44 and 37 years, respectively (18). Several 
case reports of acute and sometimes fatal acute TTP occurring during a (first) pregnancy and leading 
to the later identification of a severe constitutional ADAMTS13 deficiency caused by compound 
heterozygous or homozygous ADAMTS13 mutations (23,24) also suggest that pregnancy may be an 
important trigger for acute disease in USS. Fujimura et al. reported 9 women from 6 Japanese 
families with a pregnancy-onset of hereditary TTP (25). All 9 women became thrombocytopenic 
during the second or third trimester of all 15 pregnancies and thrombocytopenia was often followed 
by full-blown acute TTP. Eight babies were stillborn or died soon after birth, the remaining 7 were 
premature except one whose mother received regular plasma infusions  starting in early pregnancy 
(25). Of 17 congenital TTP patients diagnosed and treated in the United Kingdom, there were 6 
women with a pregnancy-onset (at ages 18-33 years), whereas 5 cases had a neonatal and 6 a 
childhood (18 months – 10 years) disease onset (26). All patients were reported as severely 
ADAMTS13 deficient and showed homozygous or compound heterozygous ADAMTS13 mutations. Of 
note, 2 pregnancy-onset cases had a homozygous and heterozygous ADAMTS13 p.R1060W mutation, 
respectively (26). Carriers of the ADAMTS13 p.R1060W mutant were shown to display small residual 
ADAMTS13 activity (27). Studying 29 hereditary TTP patients from 4 European centers (Milan, United 
Kingdom, Bergamo, France), Lotta et al. found 4 unrelated USS patients with homozygous p.R1060W 
mutations, all displaying some residual ADAMTS13 activity (about 5-7% as compared to normal 
plasma) and all having a disease onset in adulthood, pregnancy being a common trigger of a first TTP 
attack (27). A cross-sectional overview of the national registry of the French Reference Center for 
Thrombotic Microangiopathies from 2000 – 2010 including 592 adulthood-onset severely ADAMTS13 
deficient TTP patients (417 of them women, 280 women aged less than 45 years) revealed 42 women 
with a pregnancy-onset TTP (corresponding to 15% of women of childbearing age) (28). Ten of these 
42 women (24%) had USS syndrome (diagnosed retrospectively in most instances), a proportion 
much higher than that in adulthood-onset TTP in general (less than 5%). This clearly demonstrates 
that pregnancy is a common disease-trigger in USS. Eight of the 10 women carried a p.R1060W 
mutation besides a series of other mutations. Whereas all 10 pregnancy-onset USS patients survived, 
the outcome for the babies was severely compromised, with 2 miscarriages in the first trimester, 2 
intrauterine fetal deaths at 26 and 27 gestational weeks, 2 deaths shortly after birth after premature 
deliveries at 25 and 30 gestational weeks, and only 4 surviving healthy babies, all born after 33 
gestational weeks (28). Moreover, follow-up of these women with USS with a total of 7 subsequent 
pregnancies showed successful outcome for mothers and babies with regular FFP infusions during 
pregnancy but TTP recurrence without prophylaxis (28). Von Krogh et al. reported on 15 pregnancies 
in 8 Norwegian patients with diagnosed USS (29). Two of the 8 women had received a diagnosis of 
recurrent TTP before their first pregnancies, in 2 others there were probable undiagnosed earlier TTP 
attacks and 4 had true pregnancy-onset TTP. All women experienced complications during pregnancy 
and there were only 6 living infants, of which only one was born near full-term with normal birth 
weight. Prophylactic plasma infusions given in two pregnancies after a diagnosis of USS resulted in 
living even though severely premature neonates. Four of the 8 unrelated Norwegian USS patients 
had a homozygous ADAMTS13 c.4143_4144dupA mutation without any residual ADAMTS13 activity, 
and 2 others were compound heterozygotes with one c.4143_4144dupA allele. Two women carried 
one p.R1060W allele (29).  
Because several of these 8 Norwegian USS women had shown signs and symptoms suggestive of 
severe preeclampsia/HELLP syndrome during their 15 pregnancies before USS was finally diagnosed 
and given the high prevalence of hereditary TTP in Central Norway (AS von Krogh, JA Kremer Hovinga 
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et al. unpublished), the question was raised whether there were any so far undetected USS cases 
among patients diagnosed with preeclampsia or HELLP syndrome. A systematic case finding study in 
more than 1400 women discharged from St Olavs Hospital Trondheim University Hospital over a ten 
year period (2001-2010) with the diagnosis of preeclampsia, eclampsia and an additional diagnosis 
compatible with TTP was conducted (29). Twenty-nine patients fulfilled the inclusion criteria for 
ADAMTS13 screening and 17 underwent ADAMTS13 testing. None had severe ADAMTS13 deficiency. 
This clearly demonstrates that USS is not a frequent cause of the much more common hypertensive 
pregnancy complications, preeclampsia and HELLP syndrome. However, the rare women having 
severe hereditary ADAMTS13 deficiency are at a very high risk of severe pregnancy complications 
often masquerading as severe preeclampsia or HELLP syndrome (29). To make a correct diagnosis of 
USS is of utmost importance, as regular FFP infusions started in early pregnancy may not only 
prevent acute TTP attacks but also permit a normal pregnancy outcome (24,25,28,29). 
 
Pregnancy and acquired TTP 
Pregnancy may also constitute  a risk factor for the onset of acute acquired TTP caused by 
autoantibody-mediated severe ADAMTS13 deficiency. Analysis of the Oklahoma TTP-HUS registry, a 
population-based inception cohort of all consecutive patients with suspected TTP for whom PEX was 
requested, shows that 27 of 376 patients enrolled between 1989 and 2008 were categorized as 
“pregnant/postpartum” (9). Of the 261 patients included from 1995 – 2008 who had undergone 
ADAMTS13 activity testing upon admission before starting PEX, 15 were pregnant/postpartum and 
only 3/15 had a severe (acquired) ADAMTS13 deficiency (9). The cross-sectional analysis of the 
national registry of the French Reference Center for Thrombotic Microangiopathies covering the time 
period from 2000 – 2010 overviewed 592 adult-onset TTP patients with a severe ADAMTS13 
deficiency and 42 of them had a pregnancy-onset TTP (28). As mentioned above (Pregnancy and 
hereditary TTP), 10 were USS cases and 32 had severe acquired ADAMTS13 deficiency. Thus, out of 
280 women of childbearing age (less than 45 years) with acute TTP, 10 had pregnancy-onset TTP and 
severe congenital ADAMTS13 deficiency (s. above) and 32 (11.5%) had pregnancy-onset TTP with 
severe acquired ADAMTS13 deficiency (28). Even though the risk of acute disease manifestion 
triggered by pregnancy may be especially high for women with USS, pregnancy may also be a 
(possibly milder) risk factor for acquired TTP. Jiang et al. investigated all ten women from the 
Oklahoma TTP-HUS registry who became pregnant after having survived a first acute TTP episode 
with severe acquired ADAMTS13 deficiency (30). During 16 subsequent pregnancies in these 10 
women, acute TTP recurred in 2 women, 9 and 29 days post delivery, respectively. Five of the 16 
pregnancies (31%) in 3 women were complicated by (severe) preeclampsia, a much higher 
occurrence than expected. Thirteen of the 16 pregnancies resulted in normal children (30). Jiang and 
colleagues did an extensive and systematic literature search finding only 6 reports on 10 pregnancies 
in 8 women having survived a previous acute TTP with severe acquired ADAMTS13 deficiency: There 
were 6 TTP recurrences in 10 pregnancies and 2 instances of (severe) preeclampsia. This much higher 
incidence of recurrent  acquired TTP in subsequent pregnancies as compared to the Oklahoma 
Registry data may possibly be ascribed to a publication bias of individual case reports. 
Additional data were recently published by Scully and coworkers from the United Kingdom TTP 
Registry (31) including the pregnancy-onset USS cases previously published (26). Twelve women with 
acquired TTP occurring in pregnancy are presented. There were 7 live births, 4 intrauterine fetal 
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deaths and one pregnancy termination. All twelve women survived, 6 women had 8 subsequent 
pregnancies with one TTP relapse at 6 gestational weeks and one relapse postpartum as well as one 
IUFD (31). Furthermore Scully et al. report on 18 pregnancies in 12 women having recovered from an 
acute acquired TTP not related to pregnancy. These women were subjected to regular monitoring of 
the ADAMTS13 activity, at least once per trimester, if the values remained normal and more 
frequently, if they decreased. There were no relapses of TTP, in one woman with ADAMTS13 falling 
below 10%, targeted intervention with short-term PEX seemed to prevent a clinical relapse, and one 
woman developed acute lupus, needed immunosuppressive therapy but retained normal ADAMTS13 
values. Finally, a nested case-control study on 15 pregnant women out of 254 having survived an 
earlier acquired TTP was performed (Drs. Barbara Ferrari, Flora Peyvandi et al., unpublished). Four 
cases of gravidic TTP, 5 miscarriages and 6 controls with uncomplicated pregnancies were selected. It 
was shown that ADAMTS13 levels in the first trimester were severely decreased in cases with 
recurrent (gravidic) TTP, moderately reduced in those with miscarriage and normal in the controls.  
In sum, acquired TTP may probably occur slightly more often in pregnancy as compared to non-
pregnant women (28). Acute acquired TTP occurring in pregnancy may pose a high vital risk, 
especially for the fetus. Having recovered from acute acquired TTP, associated or not with 
pregnancy, the risk of recurrent TTP during a subsequent pregnancy may not be substantially 
elevated (30,31), if the generally high recurrence rate of acquired severely ADAMTS13 deficient TTP 
is taken into account (9). It is very likely, however, that the risk of preeclampsia in subsequent 
pregnancies is increased and the outcome for the babies may be compromised (30,31). Uncontrolled 
data suggest that pregnancy monitoring by regular ADAMTS13 measurement may improve the 
pregnancy outcome (31). 
 
Summary 
This short (and necessarily incomplete) review of the complex relation between pregnancy and 
thrombotic thrombocytopenic purpura shows that for a better understanding of such clinically 
important questions further prospective studies on unselected consecutive patients are essential. It 
would be desirable to not only include all consecutive patients upon admission but also to plan a 
structured and systematic follow-up. To this end, a registry has been set up for the hereditary TTP 
patients (www.ttpregistry.net; www.clinicaltrials.gov registration number NCT01257269) (32), and 
similar prospective cohorts for acquired TTP patients will increase our knowledge and improve 
patient management in the future. 
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